Skip to main content
Equibles

UBS Group AG

Position in GNLX — GENELUX Corp

CIK 1610520 ZURICH, V8
Back to GNLX Full portfolio

Position in GNLX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$105,334
-$191,306 QoQ
Shares Held
34,995
-71.5% QoQ
Ownership
0.077%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#31
of 72 holders
Holding Since
Mar 2023
14 quarters on record
Voting authority Sole 29% Shared 0% None 71%

Common Shares in GNLX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. GNLX ranks #359 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in GNLX

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $105,334 34,995
2026-03-31 $296,640 122,579
2025-12-31 $206,489 47,360
2025-09-30 $116,671 27,779
2025-06-30 $204,412 71,224
2025-03-31 $183,967 68,136
2024-12-31 $59,214 25,091
2024-09-30 $95,010 40,089
2024-06-30 $61,682 31,632
2024-03-31 $283,665 44,116
2023-12-31 $284,823 20,330
2023-09-30 $245,512 10,025
2023-06-30 $98,716 3,017
2023-03-31 $5,104 184